G1 Therapeutics, Inc. announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will be presented in a poster session during the upcoming 2024 American Society of Clinical Oncology (ASCO) Meeting. ASCO will be held May 31 to June 4, 2024, in Chicago, IL. The abstract was made available by ASCO and includes the initial Phase 2 trial results originally provided by the Company in January 2024.

The poster that will be presented at ASCO will describe the mature results of the Phase 2 trial as an update to the initial results. Poster Presentation Details: Trilaciclib Combined with Sacituzumab Govitecan (SG) in Metastatic Triple Negative Breast Cancer (mTNBC): Updated Phase 2 Safety and Efficacy Results Seneviratne, L. et al. Poster and abstract number 1091 Poster session: Breast Cancer-Metastatic June 2, 2024.

9:00 AM-12:00 PM CDT.